Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid Cancer
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer
Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.
Eric J. Sherman, MD, on Immunotherapy Trends in Head and Neck Cancer
Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space.
Eric J. Sherman, MD, Discusses the Use of Adjuvant Capecitabine in Nasopharynx Cancer
Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.